RTOG study adds further data on use of Erbitux in NSCLC

Data presented by RTOG at ASCO show Erbitux (cetuximab) addition to paclitaxel,  carboplatin and radiotherapy regimes resulted in higher median survival rates and 2yr overall survival rates than previous RTOG studies in patients with inoperable non-small cell lung cancer (NSCLC)

Amgen present data on new kinase programs

AMG-479 – IGF-1R MAb – Phase I results show the drug is safe when administered in combination with panitumumab or gemcitabine for the treatment of patients with advanced solid tumors. Some initial efficacy observed

AMG-102 – HGF/SF (c-Met receptor) – Safe when adminstered in combination with bevacizumab or motesanib in patients with advanced solid tumors. Phase [...]

Phase III data show erbitux addition to platinum based therapy increases OS

Data presented at ASCO show erbitux (cetuximab) addition to platinum based therapy increases overall survival in patients with advanced non-small cell lung cancer (NSCLC)

Phase I data on Exelixis PI3K/mTor inhibitor XL765

Data presented at ASCO show Exelixis’ PI3K/mTor inhibitor XL765 to be safe in a Phase I trials carried out in patients with metastatic or unresectable solid tumors. Initial data on efficacy shows 5/19 patients have experienced stable disease for at least 3 months.

p38 inhibition effective in renal fibrosis

Inhibition of p38 with FR167653 decrease renal fibrosis in a mouse model of unilateral ureteral obstruction

Herceptin with Omnitarg effective in Breast cancer

Phase II results presented at ASCO show Roche/Genentech’s show treatment with a combination of Herceptin and Omnitarg (pertuzumab) results in ‘impressive’ results. Almost 1/4 patients demonstrated a complete or partial tumor response

Torisel improves PFS in relapsed and refractory mantle cell lymphoma

Phase III results presented by Wyeth at ASCO show its new mTor inhibitor Torisel (temsirolimus) to be effective in the treatment of refractory and relapsed mantle cell lymphoma. Patients experienced a statistically significant improvement in median progression-free survival (PFS), compared with single-agent therapy

Torisel effective in Advanced Kidney cancer

Phase III results presented by Wyeth at ASCO show its new mTor inhibitor Torisel (temsirolimus) to be effective in the treatment of advanced renal cancer. Torisel increased median OS by 49%

Avastin significantly increases breast cancer patients chance of living without disease progression

Phase III data presented at ASCO shows that avastin (bevacizumab) significantly improves tprogression-free survival time when combined with docetaxel (Taxotere).

Phase IV results show Tarceva lengthens survival and improves QoL

New Phase IV data presented at ASCO 2008 show that non-small cell lung cancer (NSCLC) patients treated with Tarceva (erlotinib) survive longer and experience better quality of life, control of disease symptoms and control of cancer progression.